CytoMed Therapeutics And 2 Other US Penny Stocks To Watch

Simply Wall St.12-06

As the U.S. stock market takes a breather from its record-setting rally, investors are paying close attention to opportunities that may arise in various sectors. Penny stocks, despite their somewhat ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489460046?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","is_english":true,"pubTime":"2024-12-06 01:09","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2489460046","market":"us","top_or_hot":-1,"title":"CytoMed Therapeutics And 2 Other US Penny Stocks To Watch","media":"Simply Wall St.","content":"<div>\n<p>As the U.S. stock market takes a breather from its record-setting rally, investors are paying close attention to opportunities that may arise in various sectors. Penny stocks, despite their somewhat ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cytomed-therapeutics-2-other-us-170914571.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CytoMed Therapeutics And 2 Other US Penny Stocks To Watch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCytoMed Therapeutics And 2 Other US Penny Stocks To Watch\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-06 01:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cytomed-therapeutics-2-other-us-170914571.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the U.S. stock market takes a breather from its record-setting rally, investors are paying close attention to opportunities that may arise in various sectors. Penny stocks, despite their somewhat ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cytomed-therapeutics-2-other-us-170914571.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/cytomed-therapeutics-2-other-us-170914571.html","article_id":"2489460046","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489460046","pubTimestamp":1733418554,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"As the U.S. stock market takes a breather from its record-setting rally, investors are paying close attention to opportunities that may arise in various sectors. Penny stocks, despite their somewhat outdated name, continue to be a focal point for those interested in smaller or newer companies with growth potential. These stocks can offer unique opportunities at lower price points, and when backed by strong financial health and fundamentals, they present an underappreciated chance for growth without many of the typical risks associated with this segment of the market.Overview: CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company developing novel cell-based immunotherapies for cancer and degenerative diseases in Malaysia and Singapore, with a market cap of $26.53 million.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4209":"餐馆","BABB":"BAB, Inc.","LENZ":"Therapeutics","BK4563":"昨日强势股","PVL":"Enduro Royalty Trust","RAVE":"RAVE Restaurant Group","BK4551":"寇图资本持仓","IDN":"Intellicheck Mobilisa Inc","BK4213":"石油与天然气的勘探与生产","GDTC":"CytoMed Therapeutics Limited","BK4526":"热门中概股","RLX":"雾芯科技","BK4075":"烟草"},"translate_title":"CytoMed Therapeutics和另外2只值得关注的美国细价股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BABB":1,"LENZ":1,"PVL":1,"RLX":1,"GDTC":0.9,"IDN":0.9,"RAVE":0.9},"content_text":"As the U.S. stock market takes a breather from its record-setting rally, investors are paying close attention to opportunities that may arise in various sectors. Penny stocks, despite their somewhat outdated name, continue to be a focal point for those interested in smaller or newer companies with growth potential. These stocks can offer unique opportunities at lower price points, and when backed by strong financial health and fundamentals, they present an underappreciated chance for growth without many of the typical risks associated with this segment of the market.\nTop 10 Penny Stocks In The United States\n\n\n\nName\nShare Price\nMarket Cap\nFinancial Health Rating\n\n\nInter & Co (NasdaqGS:INTR)\n$4.36\n$1.96B\n★★★★☆☆\n\n\nBAB (OTCPK:BABB)\n$0.85\n$6.03M\n★★★★★★\n\n\nQuantaSing Group (NasdaqGM:QSG)\n$3.08\n$144.14M\n★★★★★★\n\n\nImperial Petroleum (NasdaqCM:IMPP)\n$2.97\n$90.69M\n★★★★★★\n\n\nGolden Growers Cooperative (OTCPK:GGRO.U)\n$4.50\n$69.71M\n★★★★★★\n\n\nZTEST Electronics (OTCPK:ZTST.F)\n$0.24\n$8.83M\n★★★★★★\n\n\nPermianville Royalty Trust (NYSE:PVL)\n$1.5309\n$51.48M\n★★★★★★\n\n\nRLX Technology (NYSE:RLX)\n$1.83\n$2.39B\n★★★★★★\n\n\nZynerba Pharmaceuticals (NasdaqCM:ZYNE)\n$1.30\n$65.6M\n★★★★★☆\n\n\nCBAK Energy Technology (NasdaqCM:CBAT)\n$0.9244\n$84.37M\n★★★★★☆\n\n\n\nClick here to see the full list of 706 stocks from our US Penny Stocks screener.\nLet's dive into some prime choices out of the screener.\nCytoMed Therapeutics\nSimply Wall St Financial Health Rating: ★★★★★☆\nOverview: CytoMed Therapeutics Limited is a pre-clinical biopharmaceutical company developing novel cell-based immunotherapies for cancer and degenerative diseases in Malaysia and Singapore, with a market cap of $26.53 million.\nOperations: The company's revenue segment is derived entirely from its Biotechnology (Startups) business line, amounting to SGD 0.45 million.\nMarket Cap: $26.53M\nCytoMed Therapeutics, with a market cap of $26.53 million, is a pre-revenue biopharmaceutical company focusing on innovative cell-based immunotherapies. Recent developments include the initiation of its ANGELICA Trial in Singapore, targeting advanced cancers using donor-derived gamma delta T cells, potentially reducing costs and improving accessibility compared to traditional CAR-T therapies. Despite its strategic advancements and sufficient cash runway for over a year, CytoMed remains unprofitable with high share price volatility and limited revenue streams under SGD 0.45 million. The management team is experienced; however, the board's average tenure suggests inexperience.\n\nJump into the full analysis health report here for a deeper understanding of CytoMed Therapeutics.\nReview our growth performance report to gain insights into CytoMed Therapeutics' future.\n\n\n\n\n  NasdaqCM:GDTC Debt to Equity History and Analysis as at Dec 2024\n \n\nRave Restaurant Group\nSimply Wall St Financial Health Rating: ★★★★★★\nOverview: Rave Restaurant Group, Inc. operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens under the Pizza Inn and Pie Five brands in the United States and internationally, with a market cap of $44.72 million.\nOperations: The company's revenue is primarily generated from Pizza Inn Franchising, which accounts for $10.41 million, followed by Pie Five Franchising at $1.60 million.\nMarket Cap: $44.72M\nRave Restaurant Group, with a market cap of US$44.72 million, has demonstrated strong financial performance in the penny stock segment. The company reported a net income increase to US$2.47 million for the year ending June 30, 2024, up from US$1.61 million previously. Earnings growth over the past year was substantial at 53.4%, surpassing industry averages and indicating robust profitability improvements with net margins rising to 21.6%. RAVE is debt-free and benefits from seasoned board leadership, although its management team lacks extensive tenure experience. Despite stable revenue figures, short-term assets comfortably cover liabilities, enhancing financial stability.\n\nGet an in-depth perspective on Rave Restaurant Group's performance by reading our balance sheet health report here.\nEvaluate Rave Restaurant Group's historical performance by accessing our past performance report.\n\n\n\n\n  NasdaqCM:RAVE Debt to Equity History and Analysis as at Dec 2024\n \n\nIntellicheck\nSimply Wall St Financial Health Rating: ★★★★★☆\nOverview: Intellicheck, Inc. is a technology company that offers on-demand digital identity validation solutions for KYC, fraud prevention, and age verification in North America, with a market cap of $54.35 million.\nOperations: The company's revenue is primarily derived from its electronic security devices segment, which generated $19.24 million.\nMarket Cap: $54.35M\nIntellicheck, Inc., with a market cap of US$54.35 million, operates in the digital identity validation sector and remains unprofitable but has reduced its losses by 7.6% annually over the past five years. Recent earnings show a slight decline in quarterly sales to US$4.71 million from US$4.76 million year-on-year, with net losses widening slightly to US$0.837 million for Q3 2024. The company is debt-free and has sufficient cash runway exceeding one year based on current free cash flow levels, though shareholders experienced dilution last year with shares outstanding increasing by 2.1%.\n\nDive into the specifics of Intellicheck here with our thorough balance sheet health report.\nUnderstand Intellicheck's earnings outlook by examining our growth report.\n\n\n\n\n  NasdaqGM:IDN Financial Position Analysis as at Dec 2024\n \n\nKey Takeaways\n\nGain an insight into the universe of 706  US Penny Stocks by clicking here.\nInvested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.\nEnhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.\n\nContemplating Other Strategies?\n\nExplore high-performing small cap companies that haven't yet garnered significant analyst attention.\nJump on the AI train with fast growing tech companies forging a new era of innovation.\nFind companies with promising cash flow potential yet trading below their fair value.\n\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.\nCompanies discussed in this article include NasdaqCM:GDTC NasdaqCM:RAVE and NasdaqGM:IDN.\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489460046"}